| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/19/2004 | WO2003063851A8 Composition for pharmaceutical or dietetic use for combating hair loss |
| 08/19/2004 | WO2003057134A8 Specific binding agents of human angiopoietin-2 |
| 08/19/2004 | WO2003053364A3 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 08/19/2004 | WO2003051886A8 Pyrazolopyridazine derivatives |
| 08/19/2004 | WO2003049702A8 Vanilloid receptor ligands and their use in treatments |
| 08/19/2004 | WO2003038123A3 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 08/19/2004 | WO2003034999A3 Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers |
| 08/19/2004 | WO2003032912A8 Treatment of cns disorders using cns target modulators |
| 08/19/2004 | WO2002092006A3 Nucleic acid-based compounds and methods of use thereof |
| 08/19/2004 | WO2002089778A3 Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| 08/19/2004 | US20040163136 SEL-12 related methods |
| 08/19/2004 | US20040162617 Mating insertion instruments for spinal implants and methods of use |
| 08/19/2004 | US20040162435 Novel aliphatic compound, method of synthesis, and method of utilization |
| 08/19/2004 | US20040162433 Lipoxin A4 analogs |
| 08/19/2004 | US20040162432 Substituted octahydrophenanthrene compounds and use thereof as NMDA antagonists |
| 08/19/2004 | US20040162430 Branched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT 1A activity |
| 08/19/2004 | US20040162427 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands |
| 08/19/2004 | US20040162426 TNF (tumor necrosis factor); for treating conditions such as rheumatoid and osteoarthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease |
| 08/19/2004 | US20040162425 6,7-Oxygenated steroids and uses related thereto |
| 08/19/2004 | US20040162422 adenosine derivatives having an acetylene group in the 4' position, which are adenosine A1 agonists; treating ischaemic heart disease, peripheral vascular disease or stroke or patient suffering pain, a CNS disorder, sleep apnoea or emesis |
| 08/19/2004 | US20040162410 Thrombosis therapy; anticoagulants |
| 08/19/2004 | US20040162355 Methods of treating and preventing cerebral function disorders using sibutramine metabolites |
| 08/19/2004 | US20040162354 Treatment of disease states which result from neoplastic cell proliferation using PPAR-gamma activators and compositions useful therefor |
| 08/19/2004 | US20040162353 Alpha-difluoromethylornithine(DFMO) suppresses polyamine levels in the human prostate |
| 08/19/2004 | US20040162351 Making a fused GABA analog prodrug having a cleavable promoiety covalently bound to the therapeutic fused GABA analog;placing prodrug in a sustained release oral dosage form; introducing dosage form into the intestinal lumen of a patient by having the patient swallow the dosage form; releasing, cleaving |
| 08/19/2004 | US20040162350 Therapy of non-cancerous disease of the prostate in a male person in need of such treatment, which is enlargement of the prostate and which comprises the administration of an amount of water-soluble amino acids |
| 08/19/2004 | US20040162349 Use of polyunsaturated fatty acid for the primary prevention of major cardiovascular events |
| 08/19/2004 | US20040162348 Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 08/19/2004 | US20040162345 Compounds with NEP/MP-inhibitory activity and uses thereof |
| 08/19/2004 | US20040162344 Effective ingredient and basic agent; foam suppression |
| 08/19/2004 | US20040162342 Platinum(II) complexes of N-substituted amino dicarboxylates and the preparation method thereof |
| 08/19/2004 | US20040162339 such as 3-[3-(1-adamantyl)-4-methoxyphenyl]-3-methyl-2H-1-benzofuran-6-carboxylic acid for treatment of psoriasis, dermatitis, acne or seborrhoea; veterinary medicine |
| 08/19/2004 | US20040162338 Flavanols and procyanidins promote homeostasis |
| 08/19/2004 | US20040162337 Lactone-type acidic compounds |
| 08/19/2004 | US20040162336 containing alcohol, water and a glycol; rapid drug delivery; bioavailability |
| 08/19/2004 | US20040162334 administering enantiomorphs comprising (Z(+-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride), as serotonin and adrenergic uptake inhibitors, with side effect reduction; antidepressants |
| 08/19/2004 | US20040162333 Rapid absorption selective 5-HT agonist formulations |
| 08/19/2004 | US20040162332 serotonin receptor ligands such as 6-(phenylsulfonyl)-2,3,4,9-tertrahydro-1H-carbazol-3-amine, used for prophylaxis of anxiety, depression, schizophrenia, Alzheimer's disease, panic, phobia, obsessive compulsive disorder, obesity, post-traumatic stress syndrome, epilepsy and nervous system disorders |
| 08/19/2004 | US20040162330 Stable high-concentration injection containing pyrazolone derivative |
| 08/19/2004 | US20040162329 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 08/19/2004 | US20040162328 Compounds of the family of 3-alkyl-(4,5-diphenyl-imidazol-1-yl) and their use as soothing agents |
| 08/19/2004 | US20040162325 phenyloxazole- or thiazole-alkyl-1,3-dioxane or 1,3-dithiane derivatives; therapeutic drugs for lowering blood triglyceride, low-density lipoprotein cholesterol; arteriosclerosis, diabetes mellitus, hypertension, obesity |
| 08/19/2004 | US20040162324 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments |
| 08/19/2004 | US20040162323 Prostaglandin D2 antagonist |
| 08/19/2004 | US20040162322 Reducing stimulant dependence; dopamine antagonist; administering pramipexole |
| 08/19/2004 | US20040162320 Dissolution profiles which can be adjusted in a range from slow to fast release according to the effect targeted for the clinical trials |
| 08/19/2004 | US20040162319 For prophylaxis and therapy of thrombotic conditions including coronary artery and cerebrovascular diseases |
| 08/19/2004 | US20040162318 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| 08/19/2004 | US20040162316 Combination treatment for alcoholism and alcohol dependence |
| 08/19/2004 | US20040162315 Administering to a patient in need thereof a therapeutically effective amount of a formulation comprising at least one compound that promotes neuron regeneration or neurite outgrowth |
| 08/19/2004 | US20040162314 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |
| 08/19/2004 | US20040162313 Heterocyclic derivatives |
| 08/19/2004 | US20040162312 NMDA NR2B antagonists for treatment |
| 08/19/2004 | US20040162310 Tetrahydropyridoethers |
| 08/19/2004 | US20040162309 Methods and compositions related to IRM compounds and toll-like receptor 8 |
| 08/19/2004 | US20040162308 Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids |
| 08/19/2004 | US20040162307 Use of methylnaltrexone and related compounds to induce laxation in chronic opioid users |
| 08/19/2004 | US20040162306 Use of methylnal trexone and related compounds to treat constipation in chronic opioid users |
| 08/19/2004 | US20040162305 Ester derivative of 1,4-disubstituted piperdine compounds; For therapy of pain |
| 08/19/2004 | US20040162304 Estrogen receptor modulators |
| 08/19/2004 | US20040162301 Minoxidil-containing liquid composition |
| 08/19/2004 | US20040162300 As inhibitor of tyrosine kinase enzymes, therapy of cancer |
| 08/19/2004 | US20040162299 Substituted quinazolines and analogs and the use thereof |
| 08/19/2004 | US20040162298 Method of treating HIV infection by preventing interaction of CD4 and gp120 |
| 08/19/2004 | US20040162297 For manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea |
| 08/19/2004 | US20040162295 Pharmaceutical compound |
| 08/19/2004 | US20040162294 Therapeutic use of selective PDE10 inhibitors |
| 08/19/2004 | US20040162293 Administering to mammal an amount of a selective PDE10 inhibitor effective in treating anxiety or psychotic disorder |
| 08/19/2004 | US20040162292 Orally administering a formulation comprising greater than 400 micrograms folic acid compound for facilitating or maintaining collagen formation to treat or prevent a collagen-related condition |
| 08/19/2004 | US20040162291 For therapy of cardiovascular disorders and erectile dysfunction |
| 08/19/2004 | US20040162290 For therapy of cancer, benign prostatic hypertrophy or myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty, lupus erythematosis, irritable bowel syndrome, premenstrual syndrome, hirsutism |
| 08/19/2004 | US20040162289 Administering a pharmaceutically effective amount of a p38 mitogen activated protein (MAP) kinase inhibitor to a patient in need of osteogenesis |
| 08/19/2004 | US20040162287 Substituted cyclohexane-1,4-diamine compounds |
| 08/19/2004 | US20040162284 Administering to the individual an effective amount of (S)-tofisopam, substantially isolated from the corresponding (R)-enantiomer of tofisopam, or a pharmaceutically-acceptable salt thereof |
| 08/19/2004 | US20040162281 Pyridine ring containing biaryl compound useful to treat and/or prevent clotting disorders, and as antiinflammatory and anticoagulant agents |
| 08/19/2004 | US20040162277 Anhydrous crystal of beta-lactam compound and method for preparation thereof |
| 08/19/2004 | US20040162276 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology |
| 08/19/2004 | US20040162275 Multivalently interactive molecular assembly, capturing agent, drug carrier, calcium chelating agent, and drug enhancer |
| 08/19/2004 | US20040162274 Inhibition of steroid synthesis by use of progesterone or a progesterone receptor agonist |
| 08/19/2004 | US20040162273 Powder pharmaceutical compositions |
| 08/19/2004 | US20040162271 Novel azole or triazole derivatives, method for preparing same and use thereof as fungicides |
| 08/19/2004 | US20040162270 Treatment of hangover after alcohol comsumption |
| 08/19/2004 | US20040162268 Extracted portion of psyllium seed with a binder and/or edible acid; polysaccharide component comprising xylose and arabinose in given ratio; specified mean particle size distribution; use for therapy of gastrointestinal disorders, as laxative |
| 08/19/2004 | US20040162267 Compositions comprising a polysaccharide component and one or more coating layers |
| 08/19/2004 | US20040162266 Compositions comprising a defined polysaccharide component |
| 08/19/2004 | US20040162265 Polymorphism crystal structure; stability |
| 08/19/2004 | US20040162264 Methods, pharmaceutical and therapeutic compositions for administering adenosine |
| 08/19/2004 | US20040162263 Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
| 08/19/2004 | US20040162262 Immunomodulatory oligonucleotides |
| 08/19/2004 | US20040162259 Administering oligonucleotide targeted to human ICAM-1 mRNA for therapy |
| 08/19/2004 | US20040162258 Immunomodulatory oligonucleotides |
| 08/19/2004 | US20040162257 For inhibiting angiogenesis |
| 08/19/2004 | US20040162255 To deliver specifically tailored small interfering RNA as therapeutic agents for treatment of Parkinson's disease |
| 08/19/2004 | US20040162254 Antiviral oligonucleotides targeting HSV and CMV |
| 08/19/2004 | US20040162253 Administering pharmacologically acceptable oligonucleotide at least 10 nucleotides in length, wherein the anti-HBV activity of oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 08/19/2004 | US20040162251 Pharmaceutical composition containing decoy and method of using the same |
| 08/19/2004 | US20040162250 Remedy and preventive for diseases caused by NF-kB |
| 08/19/2004 | US20040162248 Preparation and diabetic use of gibberellins |
| 08/19/2004 | US20040162247 Administering quercetin or at least one derivative for ameliorating the symptoms associated with osteoporosis |
| 08/19/2004 | US20040162246 Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same |